Disseminated on behalf of: TempraMed Technologies Ltd.
Ron Nagar, Founder and CEO, and Julia Becker, Vice-President Capital Markets of TempraMed Technologies Ltd. (CSE: VIVI | FSE: 9DY), discuss the company’s focus on the VIVI portfolio, its platform of battery-free products that protect temperature-sensitive injectable medications. With the rapid growth of injectable therapies such as GLP-1s driving demand, TempraMed is advancing from online sales toward retail shelves, payer partnerships, and reimbursement in 2026.
Battery-free temperature shield protects every injectable
Unlike cold-chain workarounds such as plug-in coolers, dry ice, or freezer bags, TempraMed builds protection directly into the device a patient already carries. Inside its VIVI Cap, thermal insulation is paired with a small amount of heat-absorbing material that keeps medication at a safe temperature throughout the day, with no batteries, charging, or user action required. According to Nagar, “The combination of the thermal insulation with the heat absorbing material is doing the trick and actually allowing the medication to stay safe at the proper temperature the entire day.”
The devices do two things: they shield medication and automatically capture each injection’s time and dosage, giving patients a usable record without any extra steps. Because the platform covers all injectable medications rather than a single drug, and travels with the patient without refrigeration or power, the company believes it sets a new standard for medication protection and adherence.
$30 billion injectable medication market and investor appeal
With injectable therapies reshaping treatment across diabetes, allergy, and the fast-growing GLP-1 and growth-hormone categories, TempraMed is positioned to capture demand at the point of everyday use. Hundreds of millions of patients worldwide rely on injectable medication, and, as Becker notes, “It’s a $30 billion market right now and growing.”
That growth is structural rather than cyclical, as the rise of GLP-1s and specialty peptides expands the base of patients who must transport and store sensitive medication outside the pharmacy in everyday heat and cold. TempraMed targets the under-served “last mile,” where responsibility shifts entirely to the patient and, until now, no purpose-built solution existed.
By covering the full range of injectables with one platform and layering in automatic injection tracking, the company aims to give investors early-stage exposure to a recurring device-plus-data model tied to one of health care’s most durable and early-stage demand trends.
Retail rollout, Humana partnership, and the VIVI Box launch
Recent milestones include four products in market, more than 130,000 devices sold, and validation through major channels including Amazon, Walmart, and Walgreens. The company has also partnered with Humana, the fourth-largest U.S. insurance provider, covering roughly 15 million customers, while a third party recently validated a payer return on investment of up to 40 times per year. Nagar frames the moment directly: “This year is going to be a turning point in the life of the company.”
Looking ahead, TempraMed expects to move from online sales onto pharmacy shelves across the United States, expand into additional global markets, pursue reimbursement with insurers and payers, and launch the VIVI Box, a first-of-its-kind, multi-use storage unit for several devices at once.
Positioned for digital health leadership
As TempraMed advances from a single device to a connected platform, it stands at the intersection of surging injectable-drug demand and the shift toward patient-controlled digital health. With retail expansion, payer partnerships, and the VIVI Box launch underway in 2026, the company is positioned to deliver scalable growth across both devices and data in the United States and beyond.
Transcript
Jim Gordon: Hi, I am Jim Gordon, and you’re watching Market One Minute. Joining us is Ron Nagar. He is the Founder and CEO of TempraMed. Julia Becker is the VP of Capital Markets. Welcome to you both.
Julia Becker: Thanks for having us.
Ron Nagar: Thank you.
Jim Gordon: It’s great to have you. Lots to unpack here. I’m very excited to talk to you both. Ron, I’m going to start with you. Tell us about TempraMed and your space-grade insulation that requires—I love this—no batteries.
Ron Nagar: Yes, thank you. Great questions. There are hundreds of millions of people worldwide, including kids, young adults, parents, and grandparents. All of them live active lives while relying on temperature-sensitive medications. Many of them might unknowingly be using compromised medications or tossing them away in fear of them being compromised. We developed devices that provide a temperature shield to those medications 24-7, 365 days for years without requiring any user intervention.
Some of those people may not just be required to use the medication; they may also need to record each injection they make. We’ve added a technology to our devices that can capture those injection times and dosages, without requiring any special activity. That’s an add-on. Basically, with this, our products are doing two things: First, is providing a temperature shield, and the second is recording all injection events, actually making the life of those people a little bit easier. It is unique and allows people to live worry-free.
Jim Gordon: That’s how you’re able to regulate the temperature reliably.
Ron Nagar: Yes, if you break down our products, and I have here the VIVI Cap. If you break it down, inside you will find the thermal insulation, and after the thermal insulation, there is a small amount of special material called heat-absorbing material. The combination of the thermal insulation with the heat-absorbing material is doing the trick and allowing the medication to stay safe at the proper temperature the entire day, even if you leave it in the desert, OK, or in the back of your car, which is more realistic.
Jim Gordon: Julia, I want to turn to you now. Ron touched on something, and I was mentioning to both of you before we came on camera, about that one example, and you said, ‘Someone leaves their medication in the back of their car on a summer day,’ I’m in that category of people that naively assume that your medication is safe once you leave the pharmacy, but that’s not really the case. Talk about temperature damage. I said to you, ‘I wasn’t really aware of that phrase.’ But how common is that?
Julia Becker: Great question, and when we think about temperature-sensitive medication, it really is quite finicky. Your temperature-sensitive medication is oftentimes compromised in high heat and really cold temperatures. What we’re referring to is called the ‘last mile,’ and it’s a significant problem.
Jim Gordon: Sorry to interrupt you, but this is on the customer, the patient.
Julia Becker: It’s a huge problem. Pharmacies do an excellent job making sure that the customer’s medication is safe until it’s given to the customer or patient, and they leave that pharmacy. Then the burden is completely on the patient. When we’ve been talking to people, we hear stories about people leaving the pharmacy in the summer and taking their medication into a hot car, turning the car on, using air conditioning and putting their medication as they commute home. And up until now, there has not been a solution in market. The closest solution would be plug in or dry ice, or freezer bags with ice to transport these medications.
Our solution and our platform of technology products, medical devices, that covers all injectable medication. It’s not just one specific injectable. We’ve got insulin. We have EpiPens, which is a big one. We’ve talked about GLP-1s and growth hormones, which is an industry in itself that’s growing very quickly. We cover all of that and we’ve provided a solution now for a global critical need that is growing.
Jim Gordon: You’ve mentioned some of the areas that you’re covering. You mentioned the global market. How big is that? How large is that, and where do you see the biggest growth coming from over the next few years? Julia, you take this one as well.
Julia Becker: Absolutely. Ron said, ‘Hundreds of millions of patients worldwide use injectable medication.’ It’s a $30-billion market right now and growing. In the last, while we’ve seen an explosive growth of the GLP-1s and some specific peptides, growth hormones, et cetera, we know that this industry is not going away. It’s actually going to be growing year-over-year.
Our belief is that all of our devices will be connected at one time to help manage and track not only the medication use, when you take it, where you take it, but also if you think about empowering the patient to take control of their own health care. It provides them with a long-term data set of injectable medication and what they’ve taken. Then they’re able to provide it to their health-care network, which oftentimes results in much more positive health-care outcomes for the patient.
Jim Gordon: Ron, back to you. You’ve expanded your partnership and your distribution. What does that say about the growth cycle for your company?
Ron Nagar: We are just at the very early beginning. So far, most of our devices have been available online with our partners. Now, we are moving. We’re shifting. We’re shifting this year to be in stores, not just online. We are working with additional distributors. We are expanding the network. We have many verticals to go to. We have many geographies. We started in the U.S. We are expanding globally. We have many opportunities of growth for both in the device, the need in terms of the medications coverage, the opportunity to move from online to in-store, and global expansion. Basically, we are just at the very beginning in 2026. This year is going to be a turning point in the life of the company.
Jim Gordon: For investors and our viewers watching, I want to know, is TempraMed ultimately a device company, a platform, or something broader within digital health?
Julia Becker: Yeah, so as Ron was mentioning, I think the company is at a very exciting inflection point. If you look back to even last year, we started with one device in market. Right now our platform, or portfolio of products, includes four products in market selling today. 130,000 devices have been sold already. Our products have been validated with the likes of Amazon, Walmart, and Walgreens. These are big distribution partnerships.
And as we continue going forward, towards the end of the year, we will be launching a new product, the VIVI Box, which is a first-of-its-kind, multi-use storage facility for multiple devices at one time. Then that also poses an opportunity for us, given that our technology is at core looking at other opportunities: frontline military and ambulance services. We’re looking at hospital networks for blood transfusion and organ transfer. Looking forward, I would say it started as a device, and now we’re building a platform to address the broader scope of the health-care market.
Ron Nagar: As Julia said, we started with one device; we are now moving to a platform, but with the added digital capabilities of our product and the fact that the market is moving there on the treatment cycle or the treatment regime is moving in that direction, we are going to be a significant player in the digital health space.
Jim Gordon: OK, final question, getting a little philosophical here. You’ve talked about things coming up. If three of us are sitting here a year from now, what does TempraMed look like?
Julia Becker: As we previously mentioned, we’ve been selling our devices online with incredible success on a B2C model. Exciting for this year, we do expect to have our products in stores, on shelves, across pharmacy networks in the United States. Ron alluded to the fact that we are shifting distribution globally, so we expect some more key markets to sell our devices.
And then, if you look at the business, we’ve done a pretty significant pivot from that B2C model, which will continue, but looking at more B2B: engaging more HMOs, insurance companies and insurers—payers—to really help drive awareness and sell to their customer base. We already have a partner with Humana, which is the fourth-largest insurance provider in the U.S, covering about 15 million customers. We know that that’s where the value is. We’re also working towards reimbursement for our products, which takes some time—logistics and bureaucratic red tape—but we do expect to be able to reimburse our product with the HMOs and insurance companies, first in the United States and then globally.
Ron Nagar: I may add to the last thing is that we are very encouraged by the fact that our model for return on investment to payers was just recently validated by a third party, confirming our calculation that shows that, for a payer, there can be a significant return on investment of up to 40 times the return per year for just using our product.
Jim Gordon: This is great stuff, TempraMed in the spotlight. Julia, Ron, thank you for joining us.
Julia Becker: Thanks.
Ron Nager: Thank you for having us.
About TempraMed Technologies Ltd.
TempraMed Technologies Ltd. (CSE: VIVI | FSE: 9DY) is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, thermal insulation devices that work 24-7 without batteries or external power. With a product line already in market including VIVI Cap™, VIVI Cap Smart™, VIVI Epi™, and VIVI Med™, TempraMed enables patients and health-care providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed will continue to expand globally offering a solution for medication protection and adherence.
To learn more about TempraMed, visit its website. For the latest updates, follow TempraMed online: Facebook, LinkedIn, and YouTube.
